MacroGenics, Inc. (MGNX)

NASDAQ: MGNX · Real-Time Price · USD

4.040

-0.160 (-3.81%)

Sep 15, 2026, 4:00 PM EDT - Market closed

Market Cap	257.35M +156.1%
Revenue (ttm)	175.14M +21.7%
Net Income	-14.59M
EPS	-0.23
Shares Out	63.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	264,969
Open	4.190
Previous Close	4.200
Day's Range	3.990 - 4.190
52-Week Range	1.290 - 5.080
Beta	1.23
Analysts	Buy
Price Target	8.00 (+98.02%)
Earnings Date	Aug 13, 2026

About MGNX

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG... [Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 10, 2013

Employees 293

Stock Exchange NASDAQ

Ticker Symbol MGNX

Website https://www.macrogenics.com

Full Company Profile

Financial Performance

In 2025, MacroGenics's revenue was $149.50 million, a decrease of -0.31% compared to the previous year's $149.96 million. Losses were -$74.62 million, 11.4% more than in 2024.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 98.02% from the latest price.

Price Target

$8.0

(98.02% upside)

Analyst Consensus: Buy

Stock Forecasts

News

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer...

6 days ago - GlobeNewsWire

MacroGenics price target raised to $11 from $9 at B. Riley

B. Riley raised the firm’s price target on MacroGenics (MGNX) to $11 from $9 and keeps a Buy rating on the shares following the Q2 report. The firm believes the…

4 weeks ago - TheFly

MacroGenics reports Q2 EPS 31c, consensus 26c

Reports Q2 revenue $32.83M, consensus $59.14M. “Our team delivered strong second-quarter execution: advancing our strategic priorities, strengthening our financial position, and sharpening our focus t...

4 weeks ago - TheFly

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the trea...

4 weeks ago - GlobeNewsWire

MacroGenics Earnings release: Q2 2026

MacroGenics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.

4 weeks ago - Filings

MacroGenics Quarterly report: Q2 2026

MacroGenics has published its Q2 2026 quarterly earnings report on August 13, 2026.

4 weeks ago - Filings

MacroGenics Slides: Corporate presentation

MacroGenics has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.

4 weeks ago - Filings

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...

5 weeks ago - GlobeNewsWire

MacroGenics provides update on MGC026 study

MacroGenics (MGNX) provided an update on the ongoing Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, incorporating a topoisomerase I inhibitor-based linker-payload, in patie...

7 weeks ago - TheFly

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enro...

7 weeks ago - GlobeNewsWire

MacroGenics Slides: Corporate presentation

MacroGenics has posted slides in relation to its latest quarterly earnings report, which was published on July 23, 2026.

7 weeks ago - Filings

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...

2 months ago - GlobeNewsWire

MacroGenics to receive $24.5M milestone payment from Sanofi

MacroGenics (MGNX) announced that it will receive a $24.5M regulatory milestone payment from Sanofi (SNY) following the U.S. Food and Drug Administration’s accelerated approval of TZIELD to delay the ...

Other symbols: SNY

2 months ago - TheFly

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...

2 months ago - GlobeNewsWire

MacroGenics Transcript: Stifel 2026 Targeted Oncology Virtual Forum

Significant non-dilutive capital from royalty and manufacturing deals extends runway through 2028, enabling robust investment in a diversified oncology pipeline. Key clinical updates for ADC and bispecific programs are expected in 2024, with a focus on innovation and strategic partnerships.

3 months ago - Transcripts